Loading...
Loading...
NYMOX PHARMACEUTICAL CORP
NYMOX PHARMACEUTICAL CORP. Spoken Alpha tracks NYMXF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks NYMXF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NYMXF.
curl https://api.spokenalpha.com/v1/companies/NYMXF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.31 | $0.96 | +36.9% | -4.2% | -4.5% |
| Q4 FY2026 | $1.41 | $1.04 | +35.6% | -3.7% | -4.0% |
| Q3 FY2026 | $1.60 | $1.23 | +29.8% | +5.3% | +2.4% |
| Q2 FY2026 | $1.40 | $1.02 | +37.6% | -2.9% | -3.8% |
| Q1 FY2025 | $1.48 | $1.15 | +29.0% | -5.1% | -5.6% |
| Q4 FY2025 | $1.52 | $1.21 | +25.4% | -0.2% | -0.7% |
| Q3 FY2025 | $1.57 | $1.16 | +35.5% | +0.5% | 0.0% |
| Q2 FY2025 | $1.62 | $1.25 | +29.8% | -3.6% | -5.1% |
| Q1 FY2024 | $1.49 | $1.11 | +34.2% | +6.1% | +7.4% |
| Q4 FY2024 | $1.69 | $1.32 | +28.0% | +6.5% | +5.1% |